Evidence map›Paper›PMID 20595243›Full record

ArticleClinical trials (London, England)2010

HLA genotyping in the international Type 1 Diabetes Genetics Consortium.

Josyf C Mychaleckyj, Janelle A Noble, Priscilla V Moonsamy, Joyce A Carlson, Michael D Varney, Jeff Post, Wolfgang Helmberg, June J Pierce, Persia Bonella, Anna Lisa Fear and 16 more

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes.The Journal of clinical endocrinology and metabolism · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Josyf C MychaleckyjCenter for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.
Janelle A Noble
Priscilla V Moonsamy
Joyce A Carlson
Michael D Varney
Jeff Post
Wolfgang Helmberg
June J Pierce
Persia Bonella
Anna Lisa Fear
Eva Lavant
Anthony Louey
Sean Boyle
Julie A Lane
Paul Sali
Samuel Kim
Rebecca Rappner
Dustin T Williams
Letitia H Perdue
David M Reboussin
Brian D Tait
Beena Akolkar
Joan E Hilner
Michael W Steffes
Henry A Erlich
T1DGC

Funding

Type 1 Diabetes Genetics ConsortiumU01DK062418 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RICH, STEPHEN S. · 2002 to 2007
$59.8M
The genetic basis of type 1 diabetes autoimmunity in African AmericansR01DK061722 · NIDDK · CHILDREN'S HOSPITAL &RES CTR AT OAKLAND · PI NOBLE, JANELLE A · 2003 to 2013
$3.5M
NIDDK NIH HHS R01 DK061722NIDDK NIH HHS U01 DK062418
6 · The paper itself

Abstract

backgroundAlthough human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers. PURPOSE: In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years.

methodsMethods to standardize HLA genotyping at eight loci included: central training and initial certification testing; the use of uniform reagents, protocols, instrumentation, and software versions; an automated data transfer; and the use of standardized nomenclature and allele databases. We implemented a rigorous and consistent quality control process, reinforced by repeated workshops, yearly meetings, and telephone conferences.

resultsA total of 15,246 samples have been HLA genotyped at eight loci to four-digit resolution; an additional 6797 samples have been HLA genotyped at two loci. The genotyping repeat rate decreased significantly over time, with an estimated unresolved Mendelian inconsistency rate of 0.21%. Annual quality control exercises tested 2192 genotypes (4384 alleles) and achieved 99.82% intra-laboratory and 99.68% inter-laboratory concordances. LIMITATIONS: The chosen genotyping platform was unable to distinguish many allele combinations, which would require further multiple stepwise testing to resolve. For these combinations, a standard allele assignment was agreed upon, allowing further analysis if required.

conclusionsHigh-resolution HLA genotyping can be performed in multiple laboratories using standard equipment, reagents, protocols, software, and communication to produce consistent and reproducible data with minimal systematic error. Many of the strategies used in this study are generally applicable to other large multi-center studies.

Indexed as

GenotypeInternational CooperationAlgorithmsBiological AssayClinical Laboratory TechniquesDiabetes Mellitus, Type 1EducationGlobal HealthHLA AntigensHumansPedigreePolymorphism, GeneticQuality ControlRisk AssessmentHLA Antigens

Identifiers

PMID20595243
PMCPMC2917849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.